Find clinical trials for Acute Myeloid Leukemia (AML) in Hanyang, Seoul
CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Related conditions:
Acute Myeloid Leukemia (AML) trials near Hanyang, Seoul, KOR:
to be used in future studies in study participants diagnosed with acute myeloid leukemia (AML), myelodysplastic s...
Phase 1, Phase 2
Seoul, Seoul, South Korea and 33 other locations
This study will be conducted in two parts. Part 1 will be the Dose Confirmation portion to determine recommended Phase 3 dose (RPTD) of venetoclax in...
Phase 3
Seoul, Seoul Teugbyeolsi, Korea, Republic of and 160 other locations
inhibitor of MDM2 for the treatment of adults with FLT3 mutated Acute Myeloid Leukemia. Participants must be relapsed/refr...
Phase 1, Phase 2
Seoul, Korea, Republic of and 34 other locations
with azacitidine versus with azacitidine alone in participants with acute myeloid leukemia (AML) with the isocitr...
Phase 1, Phase 2
Seoul, Korea, Republic of and 48 other locations
This is a Phase 1 dose-escalation study of PRT2527, a potent and highly selective cyclin-dependent kinase (CDK) 9 inhibitor, in participants with sel...
Phase 1
Seoul, South Korea and 23 other locations
This is an open-label, multi-center Phase 1 study of LY3410738, an oral, covalent isocitrate dehydrogenase (IDH) inhibitor, in patients with IDH1 and...
Phase 1
Seoul, Seoul-teukbyeolsi [Seoul], Korea, Republic of and 36 other locations
VEN+AZA alone for the treatment of participants with newly diagnosed Acute Myeloid Leukemia (AML) with a mutation...
Phase 3
Seoul, South Korea and 180 other locations
The purpose of this extension study is to provide venetoclax and obtain long-term safety data for subjects who continue to tolerate and derive benefi...
Phase 3
Seoul, Seoul Teugbyeolsi, Korea, Republic of and 55 other locations
Acute Myeloid Leukaemia (AML) is an aggressive and rare cancer of myeloid cells (a white blood cell responsible f...
Phase 3
Seoul, Seoul Teugbyeolsi, Korea, Republic of and 171 other locations
to determine the safety and tolerability of increasing doses of BAL0891 in patients with advanced solid tumors or relapsed or refractory acute...
Phase 1
Seoul, South Korea and 11 other locations
Clinical trials
Research sites
Resources
Legal